LIVZON PHARMA (01513): The recombinant humanized anti-FXI bispecific antibody injection has been approved to conduct clinical trials for the indication of "prevention of venous thromboembolism after total knee arthroplasty"
LIVZON PHARMA (01513) announced that recently, the company's subsidiary Zhuhai Livzon Monoclonal Antibodies Biotechnology Co., Ltd. received the Drug Clinical Trial Approval Notice (Notice No.: 2026LP03262) approved and issued by the National Medical Products Administration, agreeing to the conduct of clinical trials of the recombinant humanized anti-FXI bispecific antibody injection declared by Livzon Monoclonal Antibodies for the indication of "prevention of venous thromboembolism after total knee arthroplasty".
LIVZON PHARMA (01513) announced that recently, the company's subsidiary Zhuhai Livzon Monoclonal Antibody Biotechnology Co., Ltd. received the Drug Clinical Trial Approval Notice (Notice No.: 2026LP03262) approved and issued by the National Medical Products Administration, agreeing to the conduct of clinical trials of the recombinant humanized anti-FXI bispecific antibody injection declared by Livzon Monoclonal Antibody for the indication of "prevention of venous thromboembolism after total knee arthroplasty."
Related Articles
.png)
DAWNRAYS PHARMA (02348) repurchased 216,000 shares on October 27 for HK$202,200.
SIMCERE PHARMA (02096) repurchased 1.042 million shares on October 27 for approximately HK$10.751 million.
JF SMARTINVEST (09636) repurchased 140,700 shares on October 27 for approximately HK$3.6401 million.
DAWNRAYS PHARMA (02348) repurchased 216,000 shares on October 27 for HK$202,200.
SIMCERE PHARMA (02096) repurchased 1.042 million shares on October 27 for approximately HK$10.751 million.
JF SMARTINVEST (09636) repurchased 140,700 shares on October 27 for approximately HK$3.6401 million.
